Strategic Wealth Investment Group LLC Sells 445 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Strategic Wealth Investment Group LLC trimmed its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 11.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,307 shares of the medical instruments supplier’s stock after selling 445 shares during the period. Strategic Wealth Investment Group LLC’s holdings in West Pharmaceutical Services were worth $1,083,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Northwest Investment Counselors LLC purchased a new stake in West Pharmaceutical Services in the third quarter worth about $30,000. Retirement Wealth Solutions LLC purchased a new position in shares of West Pharmaceutical Services in the 4th quarter valued at approximately $34,000. Brooklyn Investment Group bought a new stake in shares of West Pharmaceutical Services during the third quarter valued at approximately $41,000. MassMutual Private Wealth & Trust FSB grew its stake in West Pharmaceutical Services by 60.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 209 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 79 shares during the period. Finally, Hilltop National Bank raised its holdings in West Pharmaceutical Services by 47.9% in the fourth quarter. Hilltop National Bank now owns 216 shares of the medical instruments supplier’s stock worth $71,000 after purchasing an additional 70 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

Wall Street Analysts Forecast Growth

WST has been the topic of several research reports. Citigroup began coverage on shares of West Pharmaceutical Services in a research note on Wednesday, January 8th. They set a “buy” rating and a $400.00 price objective on the stock. UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $350.00 to $390.00 in a research report on Thursday, December 12th. Bank of America raised their price objective on West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, December 13th. StockNews.com raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Friday. Finally, Wolfe Research assumed coverage on West Pharmaceutical Services in a report on Friday, December 13th. They set a “peer perform” rating for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Moderate Buy” and a consensus target price of $430.20.

West Pharmaceutical Services Trading Up 1.3 %

Shares of WST stock opened at $343.82 on Friday. The company has a current ratio of 3.00, a quick ratio of 2.23 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12-month low of $265.00 and a 12-month high of $413.70. The stock has a market capitalization of $24.90 billion, a P/E ratio of 51.01, a P/E/G ratio of 19.71 and a beta of 1.00. The firm’s 50 day moving average is $330.91 and its 200 day moving average is $314.08.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 11th. Shareholders of record on Friday, February 7th will be issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 0.24%. The ex-dividend date is Friday, February 7th. West Pharmaceutical Services’s dividend payout ratio is 12.46%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.